Atara Q4 2024 net loss $12.7M; workforce cut 50%; pauses CAR-T programs; EBVALLO BLA resubmission ongoing

Atara Biotherapeutics, Inc.

Net loss of $12.7M ($1.19/share) for Q4 2024 vs $60.5M loss in Q4 2023; full year loss $85.4M.
Cash and equivalents $42.5M at Dec 31, 2024; entered non-binding term sheet for up to $15M equity line with Redmile Group.
Workforce reduced ~50%, retaining ~35 personnel to focus on EBVALLO BLA resubmission and CAR-T wind-down.
Paused ATA3219 and ATA3431 CAR-T programs; discontinued Phase 1 NHL study for ATA3219.
FDA CRL in Jan 2025 cited third-party manufacturing issues; clinical hold on EBVALLO; regulatory update expected in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.